Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 30: 696-700, 1984;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fyhrquist, F.
Right arrow Articles by Hichens, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fyhrquist, F.
Right arrow Articles by Hichens, M.

Clinical Chemistry, Vol 30, 696-700, Copyright © 1984 by American Association for Clinical Chemistry

Inhibitor binding assay for angiotensin-converting enzyme

F Fyhrquist, I Tikkanen, C Gronhagen-Riska, L Hortling and M Hichens

We describe a new principle for the determination of enzymes, here applied to angiotensin-converting enzyme (ACE, EC 3.4.15.1) in human serum. The enzyme inhibitor binding assay is based on specific binding of labeled inhibitor to the active center of the enzyme. Serum (10-15 microL) is incubated with 125I-labeled ACE inhibitor (" 351A ," a p- hydroxybenzamidine derivative of N-(1-carboxy-3-phenylpropyl)-L-lysyl-L- proline) at pH 7.0 at 37 degrees C for 2 h in a non-equilibrated system. Inhibitor bound to ACE is separated by adsorption to coated charcoal, the radioactivity remaining in the supernate is counted, and the ACE value is calculated from a standard curve. Sensitivity for ACE in serum is 200 U/L, corresponding to 5.0 ng of ACE purified from human lung. The coefficient of variation was 3.9% within assay, and 6.4% between assays for normal ACE activities. Correlation with a comparison spectrophotometric method (Am J Med 59: 363-372, 1975) for ACE assay was excellent (r = 0.98) in 59 samples from healthy subjects and from patients with various diseases including active sarcoidosis. The novel assay principle presented here is simple and specific, and can be extended to use with various biological fluids and tissues, and to other enzymes as well.


The following articles in journals at HighWire Press have cited this article:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
O. Saijonmaa, T. Nyman, and F. Fyhrquist
Atorvastatin inhibits angiotensin-converting enzyme induction in differentiating human macrophages
Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1917 - H1921.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
O. Saijonmaa, T. Nyman, and F. Fyhrquist
Regulation of angiotensin-converting enzyme production by nicotine in human endothelial cells
Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2000 - H2004.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
O. Saijonmaa, T. Nyman, P. Stewen, and F. Fyhrquist
Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells
Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2096 - H2102.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
N. Uhlenius, O. Vuolteenaho, and I. Tikkanen
Renin-angiotensin blockade improves renal cGMP production via non-AT2-receptor mediated mechanisms in hypertension-induced by chronic NOS inhibition in rat
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2001; 2(4): 233 - 239.
[Abstract] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
O. Saijonmaa, T. Nyman, R. Kosonen, and F. Fyhrquist
Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor
Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H885 - H891.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
D. A. Walsh, J. Catravas, and J. Wharton
Angiotensin converting enzyme in human synovium: increased stromal [125I]351A binding in rheumatoid arthritis
Ann Rheum Dis, February 1, 2000; 59(2): 125 - 131.
[Abstract] [Full Text]

Home page
 CirculationHome page
S. Hafizi, J. Wharton, K. Morgan, S. P. Allen, A. H. Chester, J. D. Catravas, J. M. Polak, and M. H. Yacoub
Expression of Functional Angiotensin-Converting Enzyme and AT1 Receptors in Cultured Human Cardiac Fibroblasts
Circulation, December 8, 1998; 98(23): 2553 - 2559.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
O. Saijonmaa and F. Fyhrquist
Upregulation of angiotensin converting enzyme by atrial natriuretic peptide and cyclic GMP in human endothelial cells
Cardiovasc Res, October 1, 1998; 40(1): 206 - 210.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Wharton, K. Morgan, R. A. D. Rutherford, J. D. Catravas, A. Chester, B. F. Whitehead, M. R. D. Leval, M. H. Yacoub, and J. M. Polak
Differential Distribution of Angiotensin AT2 Receptors in the Normal and Failing Human Heart
J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 323 - 336.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by the American Association for Clinical Chemistry.